anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention provides colostrum supplement including neonatal serum from neonates which have suckled maternal colostrum. There is also provided a composition for use in the treatment of enteropathogenic diseases in animals comprising neonatal serum from neonates which have suckled maternal colostrum, preferably in adjunct with pharmaceutically or veterinarally acceptable carriers and excipients. Preferably, the serum is sourced from neonatal calves. It is further preferred that the neonatal calf serum is obtained from calves slaughtered before 6 days of age, and that the neonatal serum has at least 25 % w/w immunoglobulins on a total protein basis. Alternative to neonatal serum the immunoglobulin content of the neonatal calf serum may be isolated and incorporated into the supplement directly. This composition or supplement is suitable for all neonates, particularly calves, piglets, sheep and also humans, and for any other mammalian neonate lacking access to sufficient maternal colostrum.
PURPOSE:To provide a hemocathartic agent composed of an emulsion of a perfluorocarbon compound used as an oxygen-carrier transfusion, and capable of effectively cleaning the blood containing toxic substances. CONSTITUTION:The objective hemocathartic agent is composed of a perfluorocarbon compound emulsion obtained by emulsifying a perfluorocarbon compound such as perfluorocylcoalkane, perfluoroalkylcycloalkane, perfluoro-N-methyl perhydroquinoline, etc. to a particle size of <=0.3mu using a polymeric nonionic surface active agent (e.g. polyoxyethylene-polyoxypropylene copolymer) and/or a phospholipid (e.g. egg yolk phospholipid) as an emulsifier and a 8-22C fatty acid compound (e.g. caprylic acid) as an assistant for emulsification. The hemocathartic agent can be applied to the diseases such as hepatic insufficiency, icterus gravis, incompatibility of the blood group in transfusion, drug intoxication, etc. The blood contaminated by intoxication, etc. is released from the body, and at the same time, the perfluoro compound emulsion is infused in the vessel.
Several studies about the effects of nerve mobilizations and stretching exercises have been conducted. Evidence regarding the comparison of these two techniques is sparse and is based on different clinical experiences and a less number of studies with limited methodological design. There has been no work regarding the long term effects of these two techniques in improving lower limb motor function in Hemiplegic stroke patients. This study will contribute to describing the long term effects of these techniques on gait, motor function and quality of life in hemiplegic stroke patients and compare the effectiveness of both techniques. A total of 54 patients diagnosed with Hemiplegic stroke will be selected for the collection of data according to the inclusion criteria. Patients will be divided into two groups, Group A and Group B. Group A will receive sciatic nerve mobilization (sliding technique) and Group B will receive Proprioceptive neuromuscular mobilization Hold relax technique 3 days a week for 30 mins per day for 6 weeks. Sciatic nerve mobilizations (sliding technique) will be performed for a duration of 1 minute each for 6 such sets with 60 seconds rest period followed by every set. The Hold Relax Technique of Hamstring will be performed with each hold period lasting for 10 seconds followed by a relaxation phase of 10-15 seconds for 10 repetitions. Data will be collected at baseline, after 3weeks and at 6 weeks after intervention from both groups. Gait will be measured using TUG (Timed up and go), Quality of life will be measured using the Urdu version of SS-QOL(stroke-specific quality of life)and lower limb motor function will be measured using fugl Meyer scale(lower extremity)
PURPOSE:To keep a bar-shaped cosmetic from slipping even when it shrinks at a low temperature or the like by using a paper perforated at the lowest part of a cylinder at a part thereof contacting a cosmetic inside on the side opposite to the upper part of the cylinder at which the paper begins to be peeled off in a convex cone of a paper-wrapped bar-shaped solid cosmetic. CONSTITUTION:Cutting lines such as perforation are arranged in plurality parallel at a fixed interval being inclined slightly to a long side of a rectangular paper, a circular hole is cut between the separate cutting lines along one short side thereof, furthermore, a hole 5 is cut at a point located at the lowest part of a cylindrical shaft along the other short side thereof as a starting point of winding the paper and a separation yarn 3 is provided parallel with the short side thereof at a position a little inward. The paper is wound on a cylindrical bar and an end rim part along the short side on the side of the circular hole is bonded to wind up. Then, the bar is pulled off to form a hollow cylinder 6 and one end opening thereof is sealed up. A cosmetic tended to be a solid at a normal temperature is heated to fill and cooled and solidified to complete. A tiny hole 5 is made at a winding start point of the rear end of the paper on the cylindrical shaft thereby enabling the preventing of the slipping of a core.
The most common manifestation of overdosage of hydroxyzine pamoate is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and vasopressors ( do not use epinephrine as hydroxyzine counteracts its pressor action).Caffeine and Sodium Benzoate Injection, USP, may be used to counteract central nervous system depressant effects. 

Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes. ECG monitoring is recommended in cases of hydroxyzine overdose.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.
Adverse cardiac remodeling contributes to heart failure development and progression, partly due to inappropriate sympathetic nervous system activation. Although β-adrenergic receptor (β-AR) blockade is a common heart failure therapy, not all patients respond, prompting exploration of alternative treatments. Minocycline, an FDA-approved antibiotic, has pleiotropic properties beyond antimicrobial action. Recent evidence suggests it may alter gene expression via changes in miRNA expression. Thus, we hypothesized that minocycline could prevent adverse cardiac remodeling induced by the β-AR agonist isoproterenol, involving miRNA-mRNA transcriptome alterations. Male C57BL/6J mice received isoproterenol (30 mg/kg/day sc) or vehicle via osmotic minipump for 21 days, along with daily minocycline (50 mg/kg ip) or sterile saline. Isoproterenol induced cardiac hypertrophy without altering cardiac function, which minocycline prevented. Total mRNA sequencing revealed isoproterenol altering gene networks associated with inflammation and metabolism, with fibrosis activation predicted by integrated miRNA-mRNA sequencing, involving miR-21, miR-30a, miR-34a, miR-92a, and miR-150, among others. Conversely, the cardiac miRNA-mRNA transcriptome predicted fibrosis inhibition in minocycline-treated mice, involving antifibrotic shifts in Atf3 and Itgb6 gene expression associated with miR-194 upregulation. Picrosirius red staining confirmed isoproterenol-induced cardiac fibrosis, prevented by minocycline. These results demonstrate minocycline's therapeutic potential in attenuating adverse cardiac remodeling through miRNA-mRNA-dependent mechanisms, especially in reducing cardiac fibrosis. NEW & NOTEWORTHY We demonstrate that minocycline treatment prevents cardiac hypertrophy and fibrotic remodeling induced by chronic β-adrenergic stimulation by inducing antifibrotic shifts in the cardiac miRNA-mRNA transcriptome.
The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a topical broad−spectrum microbicide should be given prior to the injection.

Prefilled syringe: Inject by pressing the plunger carefully and with constant pressure. Do not apply additional pressure once the plunger has reached the bottom of the syringe. A small residual volume may remain in the syringe after a full dose has been injected. This is normal. Do not administer any residual solution observed in the syringe.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.

Following intravitreal injection, patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay [see Patient Counseling Information (17)].

Each sterile, prefilled syringe or vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new sterile, prefilled syringe or vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before PAVBLU is administered to the other eye.

After injection, any unused product must be discarded.
The invention discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and a preparation method thereof. The pharmaceutical composition comprises the components of, by weight, 499 parts of salviae miltiorrhizae, 249.5 parts of rhizoma chuanxiong, 249.5 parts of red peony root, 83 parts of saffron, 249.5 parts of peach kernels, 124.75 parts of rhizoma cyperi, 124.75 parts of costus root and 62.4 parts of hawthorn. A solution provided by the invention is an oral liquid preparation of the pharmaceutical composition of pure traditional Chinese medicines. The pharmaceutical composition is prepared based on a composing principle of traditional Chinese medicine formulas, and has the effects of promoting qi to activate blood, relieving depression and resolving blood-stasis, and nourishing blood to dredge vessels. The pharmaceutical composition has the functions for symptoms such as headaches, dizziness, chest pains, palpitations and the like which are caused by qi stagnation and blood stasis of cardiovascular and cerebrovascular diseases such as coronary heart diseases, atherosclerosis, pulmonary heart diseases, multi-infarct dementia and the like. Compared with Lemai granules in a pharmacopeia standard and a conventional solid preparation, the pharmaceutical composition has the advantages of small dosage, good taste, convenience for taking, relatively fast absorption, high bioavailability, stable quality, simple production process, etc.
Available clinical evidence on the use of dexmedetomidine sedation in neurosurgical and neurocritical care is limited and no definite conclusion can be drawn. There is a need for The use of dexmedetomidine might be a useful adjunct in clinical situations when the increase in CBF could be detrimental such as vasogenic cerebral edema (i.e., TBI, large brain tumors). However, dexmedetomidine sedation is questionable in patients with subarachnoid hemorrhage and acute stroke, since the associate drop in arterial pressure could worsen the coexisting increase in circulating catecholamines and massive sympathetic outflow. Further high-quality RCTs to evaluate the use of dexmedetomidine as a sedative agent both in general ICU patients and in patients with TBI.

Transcranial Doppler (TCD) is a simple noninvasive bedside tool to assess the cerebral blood flow pattern. The new development of transcranial color Doppler with angle correction option helps to improve the sensitivity of test results. TCD can assess the evolution of CBF alterations and possibly cerebral autoregulation performance and ICP estimation in patients presenting with cerebral pathology.
A medicine that may be topically applied for treatment of arthritis, dermatological problems, such as abnormal pigmentation. The medicine may comprise vegetables or fruit, including extracts of fruit or vegetable juices that have undergone a fermentation process. These ingredients are combined and processed by a device that applies a current through a metallic electrode, which contributes metal to the medicine. The topical medicine so produced may comprise jalapeno pepper and copper, and the resulting medicine is an improvement upon other pepper-based products such as capsaicin. In another process, the device may be used to remove alloys from metals. Alloys may be removed from gold, such as gold jewelry, and from other metals such as copper.
OBJECTIVES: Fatigue is a common symptom in former intensive care unit patients. Earlier research suggests that it is a lasting problem. This study aimed to further investigate the incidence of fatigue through the Multidimensional fatigue inventory (MFI-20) up to three years post intensive care.
METHOD/SAMPLE: In this prospective longitudinal study 56 former patients accepted inclusion and 55 patients filled out the questionnaire MFI-20 on one, two or three occasions; 49 at the visit at the post intensive care clinic, 21 after one year and 29 at three years after discharge from intensive care. MFI-20 can be interpreted through its total score or divided into five sub scores: general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue. Baseline characteristics were collected, and statistical significance was measured with the help of SPSS software.
RESULTS: The median ages for the three time points were 59, 61 and 62 respectively. There were more men in each group; 59, 57 and 62 %, but there were no significant differences in baseline characteristics between the groups. Based on the total fatigue score 67 % (n = 33) had severe fatigue 2-9 months after intensive care. The incidence of severe fatigue for one and three years was 48 % (n = 10) and 45 % (n = 13). Younger patients had significantly higher fatigue scores in general fatigue, reduced motivation and total score at the first two time points. After one year they also had significantly higher scores in the reduced activity subscale. Women had significantly higher fatigue scores than men in mental fatigue.
CONCLUSIONS: Fatigue is a common symptom in intensive care patients up to three years post intensive care. Younger patients have higher fatigue scores than older patients up to one year after intensive care.
IMPLICATIONS FOR CLINICAL PRACTICE: Healthcare professionals in hospitals and in out-patient care need knowledge about fatigue in former critically ill patients in order to support the management of their fatigue.
PURPOSE: To determine whether non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors affect healing rate, functional outcomes, and patient satisfaction after rotator cuff repair.
METHODS: Medline, EMBASE, PsychINFO and the Cochrane Library were searched for randomized controlled trials (RCTs) investigating the use of NSAIDs and COX-2 inhibitors after arthroscopic rotator cuff repair. Primary outcomes included healing and retear rate, determined by radiological imaging. Secondary outcomes included shoulder-specific outcome measures and the visual analog scale (VAS). Risk of bias was graded using the Cochrane risk-of-bias v2.0 tool. The GRADE framework was used to assess certainty of findings.
RESULTS: Seven RCTs with a total of 507 patients were included (298 randomized to NSAID/COX-2 vs 209 randomized to control). NSAIDs use did not yield a difference in retear rate (P = .77). NSAIDs were shown to significantly reduce pain in the perioperative period (P = .01); however, no significant difference was present at a minimum of 6 months (P = .11). COX-2 inhibitors did not significantly reduce pain (P = .15). Quantitative analysis of ASES and UCLA scores showed NSAIDs significantly improved functional outcomes versus control (P = .004). COX-2 inhibitors did not significantly improve functional outcomes (P = .15). Two trials were deemed "low" risk of bias, four trials were graded to have "some concerns", and one trial was graded to have "high" risk of bias. Retear rate and functional PROMs were deemed to have "low" certainty. VAS pain scale was graded to have "moderate" certainty.
CONCLUSIONS: This systematic review and meta-analysis indicates that NSAIDs do not affect healing rate after arthroscopic rotator cuff repair, but they do significantly improve postoperative pain and functional outcomes. No significant difference was seen in pain or functional outcomes with the use of COX-2 inhibitors.
LEVEL OF EVIDENCE: Level I, meta-analysis of randomized controlled trials.
PURPOSE: A stability improved sulglycotide, a multi-layer tablet and a manufacturing method thereof are provided to have better damaged stomach protection effects than respectively administrating the sulglycotide and a H2 receptor antagonist. CONSTITUTION: A pharmaceutical composition for treating or preventing gastrointestinal disorder comprises sulglycotide and H2 receptor antagonist as active ingredients. The H2 receptor antagonist is nizatidine, ranitidine, famotidine, cimetidine or lafutidine. The contents of sulglycotide and ranitidine are respectively 50-300mg and 20-300 mg. A multi-layer tablet which includes two or more laminated layers having active materials with different release profiles and a second layer which allows immediate release of H2 acceptor antagonist. The first layer contains 10-300mg of sulglycotide and the second layer contains 10-300mg of H2 acceptor antagonist. A manufacturing method of the multi-layer tablet comprises the following steps: manufacturing the first layer composition which includes the sulglycotide; manufacturing the second layer composition which includes the H2 receptor antagonist; introducing one of the manufactured compositions to the tablet; forming a tablet layer by compressing the introduced tablet layer composition; introducing the other manufactured composition to the tablet press; and forming bilayer tablet by compressing the introduced two compositions.
The present invention relates to a broadband functional ultrasonic patch which is in the shape of a patch and can inspect ultrasonic waves. The ultrasonic patch includes: a flexible piezoelectric device including a flexible piezoelectric layer and electrodes formed on both sides thereof; and a flexible insulation protection film to which the flexible piezoelectric device is attached. The insulation protection film can be formed with the flexible high molecular film. The ultrasonic patch has properties of broadband ultrasonic waves and can effectively irradiate a portion or a large area having a complicated shape with ultrasonic waves. The resonant frequency of the flexible piezoelectric device can be variously adjusted within 10 MHz. One side of the insulation protection film can include an ultrasonic wave coupling layer having adhesiveness to an object or skin to be irradiated with the ultrasonic waves. The coupling layer can include treating agents (such as antibiotics, anti-inflammatory agent, and a scar treating agent in a single or composite substance) having a pharmaceutical effect to biological tissue. Therefore, the patch can increase permeability and absorption of the treating agent.
Children between 11-17 years of age will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect their physical, emotional, or mental well-being (BRIEF-II and CBCL questionnaires). The child will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality.
Hoarding disorder (HD) is a chronic, progressive, and debilitating psychiatric condition that leads to devastating personal and community consequences, particularly for older adults. HD is defined by persistent difficulty discarding or parting with possessions due to distress associated with discarding, urges to save, and/or difficulty making decisions about what to keep and what to discard. As a result, clutter accumulates and fills active living areas, preventing the normal use of space and resulting in distress and disability. Community epidemiological reports estimate the prevalence of clinically significant hoarding symptoms at 7% in individuals over age 60 and even higher rates in those over age 70. HD is the only neuropsychiatric condition that progresses in severity and population prevalence with age apart from dementia.

Inhibition and cognitive switching have been identified as key deficits in older adults with HD. These executive functioning areas are consistent with the RDoC cognitive control domain and particularly the goal selection, updating, representation, and maintenance subconstruct. Findings suggest that these deficits may contribute to the symptomatic expression of HD, degree of functional impairment, and modest responses to HD treatment. Furthermore, anticipatory and experiential fear and anxiety, consistent with the RDoC constructs of acute and potential threat, lead to sustained problems with discarding items and clutter accumulation. When these constructs are targeted, our group has produced clinically and statistically significant outcomes.

Consistent with NIMH strategic goal 3.1, to arrive at effective treatment approaches for unmet therapeutic domains in behavioral science, this project seeks to conduct the first confirmatory efficacy trial for older adults with HD. We propose a RCT comparing CREST to a case management control condition for 150 adults age 50 and older with HD. We are examining age as a moderator and will therefore include both midlife and late life participants. An evaluation of treatment outcome, including hoarding severity and functional outcomes, will be conducted at baseline (0 months), mid-treatment (3 months), end of treatment (6 months), 3-month (9 months) and 6-month follow-up (12 months). Participants will receive 26 weekly 60-minute individual sessions over the course of 32 weeks maximum (6-7.5 months). They will receive 50% in home and 50% office visits. We will examine factors that mediate improvement in CREST (improved inhibition/cognitive switching and reduction in fear/anxiety of discarding items) through physiological, behavioral, self-report, and paradigm assessments. Individual factors (e.g., age and other demographic factors, baseline cognitive control, baseline hoarding severity) and treatment factors (e.g., session attendance) will be evaluated as moderators. The specific aims include determining confirmatory efficacy of CREST, mechanisms of CREST effects, and moderators of CREST. If successful, this project would lead to an effectiveness trial in a real world setting.